Gracell Biotechnologies
(NASDAQ) GRCL
This security has been delisted. This page is retained for historical reference.
GRCL News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowGRCL Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-38%
Return on Capital
-44%
Return on Assets
-37%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$0.00
Operating Income
$624.66M
EBITDA
$568.67M
Operating Cash Flow
$3.31B
Capital Expenditure
$331.55M
Free Cash Flow
$3.64B
Cash & ST Invst.
$1.46B
Total Debt
$182.98M
Gracell Biotechnologies Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
314
N/A
Net Income
$67.63M
+60.7%
EBITDA
$109.45M
+33.3%
Quarterly Fundamentals
Net Cash
$1.59B
+11.7%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$35.37M
-37.9%
Short Term Debt
$80.45M
-45.2%
Return on Assets
-36.68%
N/A
Return on Invested Capital
-43.51%
N/A
Free Cash Flow
$0.00
N/A
Operating Cash Flow
$0.00
N/A